WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H529704
CAS#: 195875-68-4 (free base)
Description: NS-2359, also known as GSK 372475, is a monoamine reuptake inhibitor (MRI) potentially for the treatment of cocaine abuse.
Hodoodo Cat#: H529704
Name: NS-2359 free base
CAS#: 195875-68-4 (free base)
Chemical Formula: C16H21Cl2NO
Exact Mass: 313.10
Molecular Weight: 314.250
Elemental Analysis: C, 61.15; H, 6.74; Cl, 22.56; N, 4.46; O, 5.09
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 195875-68-4 (free base) 195875-69-5 (citrate) 195875-97-9 (sulfate)
Synonym: NS-2359; GSK-372475; NS2359; GSK372475; NS 2359; GSK 372475
IUPAC/Chemical Name: (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
InChi Key: PGYDXVBZYKQYCS-VPWBDBDCSA-N
InChi Code: InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
SMILES Code: CN1[C@]2([H])C[C@H](C3=CC=C(Cl)C(Cl)=C3)[C@@H](COC)[C@@]1([H])CC2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 314.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol. 2012 May;26(5):653-62. doi: 10.1177/0269881111424931. PubMed PMID: 22048884.
2: Wilens TE, Klint T, Adler L, West S, Wesnes K, Graff O, Mikkelsen B. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav Brain Funct. 2008 Jun 13;4:24. doi: 10.1186/1744-9081-4-24. PubMed PMID: 18554401; PubMed Central PMCID: PMC2442604.
